BIO 2022 Notebook: Deal Values In The Eyes Of The Beholders

As 2022 proves to be a year of missed predictions and uncertainty, we are using this year's BIO notebook to provide additional context by reviewing different industry metrics to provide more perspective to the comments coming from the meeting. 

Big pharma and specialty pharmaceutical companies have made it clear that they are hunting for new technologies and drug candidates to expand their R&D pipelines in anticipation of upcoming patent expirations for key commercial products, with a focus on licensing, collaboration and bolt-on acquisitions rather than mega-mergers